Dr. Mary T Jenkins Vogel, MD
Claim this profileNorthShore University HealthSystem-Evanston Hospital
Area of expertise
Ovarian Cancer
Mary T Jenkins Vogel, MD has run 7 trials for Ovarian Cancer. Some of their research focus areas include:
Ovarian Carcinoma
Mary T Jenkins Vogel, MD has run 5 trials for Ovarian Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
NorthShore University HealthSystem-Evanston Hospital
NorthShore University HealthSystem-Highland Park Hospital
Clinical Trials Mary T Jenkins Vogel, MD is currently running
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
More about Mary T Jenkins Vogel, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Mary T Jenkins Vogel, MD has experience with
- Carboplatin
- Paclitaxel
- Olaparib
- Pembrolizumab
- Biospecimen Collection
- Cediranib Maleate
Breakdown of trials Mary T Jenkins Vogel, MD has run
Ovarian Cancer
Ovarian Carcinoma
Fallopian Tube Cancer
Endometrial Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary T Jenkins Vogel, MD specialize in?
Mary T Jenkins Vogel, MD focuses on Ovarian Cancer and Ovarian Carcinoma. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Mary T Jenkins Vogel, MD currently recruiting for clinical trials?
Yes, Mary T Jenkins Vogel, MD is currently recruiting for 3 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that Mary T Jenkins Vogel, MD has studied deeply?
Yes, Mary T Jenkins Vogel, MD has studied treatments such as Carboplatin, Paclitaxel, Olaparib.
What is the best way to schedule an appointment with Mary T Jenkins Vogel, MD?
Apply for one of the trials that Mary T Jenkins Vogel, MD is conducting.
What is the office address of Mary T Jenkins Vogel, MD?
The office of Mary T Jenkins Vogel, MD is located at: NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the NorthShore University HealthSystem-Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.